Twelve-month observational study of children with cancer in 41 countries during the COVID-19 pandemic

Keyphrases

• All-cause Mortality 100%
• Children with Cancer 100%
• COVID-19 100%
• 41 Countries 100%
• Multivariable 66%
• Childhood Cancer 66%
• Multidisciplinary Team 66%
• SARS-CoV-2 Infection 66%
• Team Planning 66%
• 12-month Follow-up 33%
• Retinoblastoma 33%
• Newly Diagnosed 33%
• Chemotherapy 33%
• Neuroblastoma 33%
• Ewing Sarcoma 33%
• Prospective Cohort Study 33%
• Non-Hodgkin Lymphoma 33%
• 30-day Mortality 33%
• Median Time 33%
• Glioma 33%
• Cause of Death 33%
• Exclusion Criteria 33%
• Primary Outcome Measure 33%
• Acute Lymphoblastic Leukemia 33%
• Low-income 33%
• Anticancer Therapy 33%
• Timely Treatment 33%
• Medulloblastoma 33%
• Osteosarcoma 33%
• Hodgkin Lymphoma 33%
• Infections in children 33%
• Low-income Countries 33%
• Wilms Tumor 33%
• Rhabdomyosarcoma 33%
• Active Treatment 33%
• Low-middle Income 33%
• Laboratory Confirmation 33%
• 12-month Mortality 33%
• Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) 33%
• Upper-middle-income 33%
• Childhood Cancer Mortality 33%

Medicine and Dentistry

• Malignant Neoplasm 100%
• Childhood Cancer 100%
• Observational Study 100%
• All Cause Mortality 100%
• Severe Acute Respiratory Syndrome Coronavirus 2 100%
• COVID-19 100%
• Infection 66%
• Cancer Mortality 33%
• Immunotherapy 33%
• Mortality Rate 33%
• Ewing Sarcoma 33%
• Ganglioneuroblastoma 33%
• Prospective Cohort Study 33%
• Non-Hodgkin Lymphoma 33%
• Cancer Treatment 33%
• Ganglioglioma 33%
• Hodgkin's Lymphoma 33%
• Rhabdomyosarcoma 33%
• Osteosarcoma 33%
• Retinoblastoma 33%
• Acute Lymphoblastic Leukemia 33%
• Wilms' Tumor 33%
• Medulloblastoma 33%
• Chemotherapy 33%
• Active Treatment 33%